05:53 PM EDT, 06/09/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) late Monday said the US Court of Appeals for the Federal Circuit has upheld a trial court ruling that confirmed the validity of the patent allowing the company to be the sole producer of its Nuplazid medication to treat hallucinations in adults with Parkinson's disease through 2038.

In the judgment handed down on Monday, US District Judge Greggory Williams wrote that the defendants, privately held MSN Laboratory and India-based Aurobindo Pharma USA, infringed on Acadia's patent by filing abbreviated new drug applications to make and sell a generic form of Nauplazid.

Acadia filed suit in federal court in Delaware in July 2020 against Aurobindo, MSN and three other drug makers, later settling with two of those firms while another, Teva Pharmaceuticals (TEVA), agreed to accept the results of the cases against Aurobindo and MSN, which were heard during a bench trial in December 2024.

The defendants still can appeal Monday's ruling to the US Supreme Court.